Table 2

Baseline TAC signatures association with clinical variables over 30 months ICS±LABA treatment compared with baseline

	TAC1			TAC2			TAC3			ICS TAC1
	rho	P value	FDR	rho	P value	FDR	rho	P value	FDR	r	P value	FDR
FEV₁ %predicted	−0.0414	0.8161	0.8161	−0.0778	0.662	0.8711	−0.3901	0.0226	0.0904	−0.3475	0.044	0.176
RV/TLC %predicted	−0.3445	0.046	0.06133	0.2131	0.2262	0.8074	0.2648	0.1302	0.1736	−0.0782	0.6603	0.6603
Log sputum eosinophils counts	−0.3968	0.0365	0.06133	0.1642	0.4037	0.8074	0.3454	0.0718	0.1436	0.1503	0.4453	0.6603
Log sputum neutrophil counts	−0.4314	0.0173	0.06133	0.0309	0.8711	0.8711	0.2405	0.2005	0.2005	−0.0974	0.6088	0.6603

FEV₁, forced expiratory volume in 1 s; ICS, inhaled corticosteroids; LABA, long-acting β-agonist ; RV/TLC, residual volume/total lung capacity; TAC, transcriptome-associated cluster.